Alumis (ALMS) Shares Outstanding (2023 - 2026)
Alumis' (ALMS) quarterly Shares Outstanding (Entity) came in at $124.4 million in Q2 2026, up 62.55% year-over-year from $76.6 million in Q2 2025, and up 25.6% quarter-over-quarter from $99.1 million in Q4 2025.
Analysis
Alumis (ALMS) Shares Outstanding (2023 - 2026) Analysis & Trends
Alumis (ALMS) has reported Shares Outstanding (Entity) for 4 consecutive years, with $124.4 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Shares Outstanding (Entity) rose 62.55% year-over-year to $124.4 million in Q2 2026; TTM through Jun 2026 was $124.4 million, a 62.55% increase from a year earlier, with the FY2025 full-year figure at $99.1 million, up 246.69% from the prior year.
- Shares Outstanding (Entity) was $124.4 million for Q2 2026 at Alumis, up from $99.1 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $124.4 million in Q2 2026 and troughed at $5.4 million in Q2 2023.
- A 4-year average of $46.3 million and a median of $37.9 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Across the five-year window, Shares Outstanding (Entity) jumped 782.33% in 2024 and jumped 62.55% in 2026, its largest moves.
- Over 4 years, Shares Outstanding (Entity) stood at $5.4 million in 2023, then soared by 434.01% to $28.6 million in 2024, then soared by 246.69% to $99.1 million in 2025, then gained by 25.6% to $124.4 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $124.4 million (Q2 2026), $99.1 million (Q4 2025), and $97.2 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 540.00 Mn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 1.24 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 253.70 Mn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 102.80 Mn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 61.30 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 398.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 147.70 Mn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 720.78 Mn |
| 10 | Alumis | 1.27 Bn | 765.76 Mn | - | 127.70 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 127.70 Mn |
| Dec 31, 2025 | 85.10 Mn |
| Sep 30, 2025 | 104.15 Mn |
| Jun 30, 2025 | 76.56 Mn |
| Mar 31, 2025 | 54.41 Mn |
| Dec 31, 2024 | 28.58 Mn |
| Sep 30, 2024 | 53.97 Mn |
| Jun 30, 2024 | 2.70 Mn |
| Mar 31, 2024 | 2.68 Mn |
| Dec 31, 2023 | 2.65 Mn |
| Sep 30, 2023 | 2.65 Mn |
| Jun 30, 2023 | 2.64 Mn |